z-logo
Premium
Oral vitamin D increases the frequencies of CD 38 + human B cells and ameliorates IL ‐17‐producing T cells
Author(s) -
Drozdenko Gennadiy,
Heine Guido,
Worm Margitta
Publication year - 2014
Publication title -
experimental dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.108
H-Index - 96
eISSN - 1600-0625
pISSN - 0906-6705
DOI - 10.1111/exd.12300
Subject(s) - cholecalciferol , vitamin d and neurology , medicine , endocrinology , cd38 , cytokine , vitamin , t cell , immunology , vitamin d deficiency , immune system , biology , stem cell , cd34 , genetics
Vitamin D deficiency (serum 25‐hydroxyvitamin D < 50 n m ) has been associated with the onset of immunological diseases including atopic dermatitis ( AD ), cutaneous or systemic lupus erythematosus and allergic asthma. In this study, we assessed whether oral vitamin D (cholecalciferol) supplementation leads to a systemic modulation of the phenotype of circulating lymphocyte populations and whether a defined serum 25‐hydroxyvitamin D (25( OH ) D ) concentration can be related to the effects on lymphocytes. Cholecalciferol was administered in a dose‐escalation setting to vitamin D –deficient individuals from 2000 up to 8000 IU daily for 12 weeks. Individuals without cholecalciferol intake served as controls. Peripheral B cells and T cells were examined by multicolour flow cytometric analysis. The mean serum 25( OH ) D concentrations increased upon cholecalciferol intake up to 159 ± 28.7 n m , and remained low in the control group 30.0 ± 12.5 n m . Following cholecalciferol intake, the frequencies of circulating CD 38 expressing B cells were significantly increased and IFN ‐ γ + , and/or IL ‐17 + CD 4 + T helper cells were decreased. These data were identified to correlate with the serum 25( OH ) D levels by applying two different analysis approaches ( ROC and a nonlinear regression analysis). Our data indicate that increasing 25( OH ) D serum concentrations are associated with an increased expression of CD 38 on B cells and a decreased T ‐cell‐dependent proinflammatory cytokine production. The therapeutical role of our findings in systemic immunological diseases should be explored in the future by further controlled clinical studies.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here